Replies to post #168867 on Biotech Values

[madrose1]

Clovis data competitive with AstraZeneca drug, says Citigroup
Citigroup views last night's data from Clovis (CLVS) as competitive with AstraZeneca's (AZN) AZD9291 in terms of efficacy and safety. Citi believes the lung cancer market is sizable enough to make both drugs big sellers and keeps a Buy rating on Clovis with a $109 price target. :theflyonthewall

[jbog]

So it only took one quarter for Tecfidera sales to exceed Gilenya's U.S. sales of $273 mil.

Wow